Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: avastin + cancer + colorectal  Related to the article below (Last Update: 8/5/2008)

NDP push NS gov't to start funding cancer treatment drug Avastin
The Canadian Press, HALIFAX - Jul 22, 2008
Marlene George, 47, of Halfway Cove in Guysborough County, was diagnosed with colorectal cancer in April 2007. She has been taking Avastin treatments for ...
Still waiting for Avastin cost relief TheChronicleHerald.ca
all 9 news articles »
ASCO 2008: The Evolving Role of EGFR Inhibitors in Colorectal Cancer
Cancer Consultants, ID - Jul 31, 2008
The CAIRO2 study was a Phase III trial that was conducted to further evaluate the addition of Erbitux to Avastin-containing regimens in colorectal cancer. ...
A Second Chance to Buy Wyeth?
Barron's - Aug 3, 2008
Case in point: Genentech's blockbuster cancer drug, Avastin, displayed virtually no dose response in trials for either breast or colorectal cancer, ...

Sify
Genentech mulls Roche offer as stock surges
The Associated Press - Jul 21, 2008
Avastin is already approved to treat lung and colorectal cancer and is being tested for colorectal cancer as an adjuvant treatment, or a treatment to ...
Roche Seeks Bargain as Genentech Investors Want More (Update2) Bloomberg
Roche Bids for Rest of Genentech (Update) TheStreet.com
What makes Genentech so great? BloggingStocks
Wall Street Journal Blogs - Trading Markets (press release)
all 912 news articles »  DNA - OTC:RHHBY - SWF:RO
Drug stocks mixed; Genentech slides on Avastin concerns
MarketWatch - Jul 7, 2008
Avastin has been most effective in the treatment of colorectal cancer. Genentech is majority owned by Swiss conglomerate Roche.
Costly cancer drug offers hope, but also a dilemma Sarasota Herald-Tribune
all 73 news articles »  DNA
NS health minister says Avastin funding available in two weeks
The Canadian Press, HALIFAX - Jul 24, 2008
HALIFAX ? Nova Scotia's health minister confirms funding for the cancer drug Avastin will be available in the next two weeks. Most of the details for the ...

RTT News
Genentech rises on 2Q results and higher outlook
Forbes, NY - Jul 15, 2008
He also expects good late-stage trial data for Avastin in colorectal cancer, where it is being tested as an adjuvant treatment, or a treatment to prevent ...
In Tough Times, Genentech and J&J Keep Rolling Wall Street Journal Blogs
Genentech's Profit Rises 4.6%; Company Boosts Year Outlook Wall Street Journal
Genentech's Q2 2008 earnings transcript BloggingStocks
FiercePharma - MarketWatch
all 130 news articles »  DNA - JNJ
Erbitux?/Avastin? Combo Not Effective in Colorectal Cancer
Cancer Consultants, ID - Jul 7, 2008
The CAIRO2 study was a Phase III trial that was conducted to further evaluate the addition of Erbitux to Avastin-containing regimens in colorectal cancer. ...
New cancer therapy not funded in province
Leduc Representative, Canada - Jul 18, 2008
If you are interested in learning more about colorectal cancer or Avastin go to www.colorectal-cancer.ca. From there you can join the fighting to get ...
Imclone Fights Erbitux Uncertainty, Notorious Past
CNNMoney.com - Jul 23, 2008
Erbitux last month was shown to be ineffective in the approximately 40% of colorectal cancer patients with a specific mutatedgene. ...IMCL
Source: Google News

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer -
H Hurwitz, L Fehrenbacher, W Novotny, T Cartwright … - The New England Journal of Medicine, 2004 - nejm.org
... Compassionate use of bevacizumab (Avastin(R)) in children and young ... in patients with
unresectable hepatic metastases from colorectal cancer previously treated ...
-

… Fluorouracil (FU)/Leucovorin (LV) With FU/LV Alone in Patients With Metastatic Colorectal Cancer -
F Kabbinavar, HI Hurwitz, L Fehrenbacher, NJ … - Journal of Clinical Oncology, 2003 - jco.ascopubs.org
... Bevacizumab (Avastin, Genentech, South San Francisco, CA), a recombinant humanized ...
FU)/leucovorin (LV) as first-line therapy for metastatic colorectal cancer. ...

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy -
N Ferrara, KJ Hillan, W Novotny - Biochemical and Biophysical Research Communications, 2005 - Elsevier
... anti-VEGF monoclonal antibody (bevacizumab; Avastin) has been approved by the FDA
as a first-line treatment for metastatic colorectal cancer in combination ...

Systemic Therapy for Colorectal Cancer -
JA Meyerhardt, RJ Mayer - New England Journal of Medicine, 2005 - content.nejm.org
... 96 Bevacizumab (Avastin), a humanized antibody directed against the vascular ... in several
clinical trials in patients with advanced colorectal cancer (Table 4 ...

… With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer -
HI Hurwitz, L Fehrenbacher, JD Hainsworth, W Heim, … - Journal of Clinical Oncology, 2005 - jco.ascopubs.org
... IFL alone in first-line treatment of patients with metastatic colorectal cancer
(CRC ... Bevacizumab (Avastin; Genentech Inc, South San Francisco, CA) 5 mg/kg was ...

Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer -
C Emmanouilides, M Pegram, R Robinson, R Hecht, F … - Techniques in Coloproctology, 2004 - Springer
... tumour reduction of colon cancer xenograft models ... with chemotherapy [5]. Bevacizumab
(Avastin, Genentech, South ... the treatment of metastatic colorectal can- cer ...

Surgical wound healing complications in metastatic colorectal cancer patients treated with … -
FA Scappaticci, L Fehrenbacher, T Cartwright, JD … - J Surg Oncol, 2005 - ncbi.nlm.nih.gov
... scappaticci.frank@gene.com BACKGROUND: Bevacizumab (Avastin; rhuMab VEGF), a ... based
chemotherapy in first-line metastatic colorectal cancer (CRC) treatment. ...

TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN). -
RPA MANZANO, GA PEYMAN, P KHAN, M KIVILCIM - RETINA, 2006 - retinajournal.com
... Bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) is a full ... Food and
Drug Administration for the treatment of metastatic colorectal cancer and is ...

… RCTs) of bevacizumab (BV) with chemotherapy (CT) in patients (pts) with metastatic colorectal cancer … -
J Hambleton, J Skillings, F Kabbinavar, E … - Journal of Clinical Oncology, 2005 - pediatricca.asco.org
... 2. Safety of bevacizumab (BV, Avastin?) among patients (pts) receiving first-line
chemotherapy (CT) for metastatic colorectal cancer (mCRC) - preliminary ...

Two Steps Forward in the Treatment of Colorectal Cancer -
RJ Mayer - The New England Journal of Medicine, 2004 - nejm.org
... Administration (FDA) has approved four new treatments for advanced colorectal cancer. ...
other two (cetuximab [Erbitux] and bevacizumab [Avastin]) are monoclonal ...
-

Source: Google Scholar
 
 

Metastatic colorectal cancer - NICE: insufficient evidence to recommend Avastin and Erbitux

 
 
The Appraisal Committee has prepared a Final Appraisal Determination on the use of Avastin and Erbitux in metastatic colorectal cancer and submitted it to the Institute.

The main recommendations made are as follows:


Avastin ( Bevacizumab ) in combination with 5-FluoroUracil plus Folinic Acid, with or without Irinotecan, is not recommended for the first-line treatment of metastatic colorectal cancer.

Erbitux ( Cetuximab ) in combination with Irinotecan is not recommended for the second-line or subsequent treatment of metastatic colorectal cancer.

People currently receiving Bevacizumab or Cetuximab should have the option to continue therapy until they and their consultants consider it appropriate to stop.


The management of metastatic colorectal cancer is mainly palliative and involves a combination of treatments ( such as palliative surgery, chemotherapy and radiation ), symptom control and psychosocial support.
The aim is to improve both the duration and quality of the individual’s remaining life.
Clinical outcomes such as overall survival, response and toxicity are important, but alternative outcomes such as progression-free survival, quality of life, convenience, acceptability and patient choice are also important.

The most frequent site of metastatic disease is the liver. In up to 50% of patients with metastatic disease, the liver may be the only site of spread.
For these patients surgery provides the only chance of longer-term survival.
Approximately 10% of patients with metastatic colorectal cancer present with potentially resectable liver metastases and for approximately 14% chemotherapy may render unresectable liver metastases operable.

Individuals with metastatic disease who are sufficiently fit ( normally those with World Health Organization performance status 2 or better ) are usually treated with active chemotherapy as first- or second-line therapy.

First-line active chemotherapy options include infusional 5-FluoroUracil plus Folinic Acid or Leucovorin ( Calcium Folinate ) ( 5-FU/FA, 5-FU/LV ), Oxaliplatin plus infusional 5-FU/FA ( FOLFOX ), and Irinotecan plus infusional 5-FU/FA ( FOLFIRI ).
Oral analogues of 5-FU ( Capecitabine and Tegafur with Uracil ) may also be used instead of infusional 5-FU.
For those patients first receiving FOLFOX, Irinotecan may be a second-line treatment option, whereas for patients first receiving FOLFIRI, FOLFOX may be a second-line treatment option.
Patients receiving 5-FU/FA or oral therapy as first-line treatment may receive treatment with FOLFOX and Irinotecan as second-line and subsequent therapies.

Survival estimates for patients with metastatic colorectal cancer receiving best supportive care are approximately 6 months.
The use of infusional 5-FU/FA can increase survival to approximately 10 -12 months, whereas combinations of FOLFIRI followed by FOLFOX, or FOLFOX followed by Irinotecan, have been reported to increase survival to 20 -21 months.

Source: NICE, 2006
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News6 ; News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page